Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers

Clinical Therapeutics

Volumn 29, Issue 6, 2007, Pages 1040-1056

  Nakamura, Masakazu ^a   Oshima, Akira ^a   Fujimoto, Yoko ^b   Maruyama, Nami ^b   Ishibashi, Taro ^b   Reeves, Karen R ^c  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b PFIZER INC   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Japan; nicotinic partial agonist; smoking cessation; varenicline

Indexed keywords

ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST; AMFEBUTAMONE; CARBON MONOXIDE; NICOTINE; NICOTINIC AGENT; PLACEBO; UNCLASSIFIED DRUG; VARENICLINE;

ABDOMINAL PAIN; ABSTINENCE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGY; ANGINA PECTORIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLEEDING; CHOLECYSTITIS; CLINICAL TRIAL; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEMATOMA; HEMORRHOID; HUMAN; INCREASED APPETITE; INFLUENZA; INSOMNIA; JAPAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; OVARIAN HEMATOMA; PERITONITIS; PITUITARY HEMORRHAGE; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; RECTUM PROLAPSE; RESTLESSNESS; RHINOPHARYNGITIS; SENSORY DYSFUNCTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUBARACHNOID HEMORRHAGE; TOBACCO DEPENDENCE; WEIGHT GAIN; WITHDRAWAL SYNDROME;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; MIDDLE AGED; NICOTINIC AGONISTS; QUINOXALINES; RECEPTORS, NICOTINIC; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 34547562775     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.06.012     Document Type: Article

References (36)

1. Mackay J., Eriksen M., and Shafey O. The Tobacco Atlas. 2nd ed. (2006), American Cancer Society
2. http://www.mhlw.go.jp/houdou/2007/05/h0516-3a.html
3. Ministry of Health Labour and Welfare. National Nutrition Survey for 1989 [Japan Health Promotion & Fitness Foundation Web site]. Available at. www.health-net.or.jp/tobacco/product/pd100000.html Accessed June 2, 2007.
4. www.ctsu.ox.ac.uk/~tobacco
5. Institute for Health Economics and Policy. Report on the cost-benefit analyses on tobacco control policies [IHEP Web site]. Available at. www.ihep.jp Accessed April 20, 2007
6. discussion 622-623. Izumi Y., Tsuji I., Ohkubo T., et al. Impact of smoking habit on medical care use and its costs: A prospective observation of National Health Insurance beneficiaries in Japan. Int J Epidemiol 30 (2001) 616-621
7. CD000146. Silagy C., Lancaster T., Stead L., et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 3 (2004)
8. CD000031. Hughes J., Stead L., and Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 4 (2007)
9. DHHS publication (CDC) 88-8406. US Dept of Health and Human Services. The health consequences of smoking: Nicotine addiction: A report of the Surgeon General (1988), Government Printing Office, Washington, DC
10. Henningfield J., Schuh L., and Jarvik M. Pathophysiology of tobacco dependence. In: Bloom F., and Kupfer D. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven, New York, NY 1715-1729
11. Maskos U., Molles B., Pons S., et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 436 (2005) 103-107
12. Coe J., Brooks P., Vetelino M., et al. Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48 (2005) 3474-3477
13. Rollema H., Chambers L., Coe J., et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52 (2007) 985-994
14. for the Varenicline Phase 3 Study Group. Jorenby D., Hays J., Rigotti N., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial [published correction appears in JAMA. 2006;296:1355]. JAMA 296 (2006) 56-63
15. for the Varenicline Phase 3 Study Group. Gonzales D., Rennard S., Nides M., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 296 (2006) 47-55
16. www.wma.net/e/policy/b3.htm
17. International Conference on Harmonisation. The ICH process for harmonisation of guidelines [ICH Web site]. Available at. www.ich.org/cache/compo/276-254 Accessed June 4, 2007.
18. Kawakami N., Takatsuka N., Inaba S., and Shimizu H. Development of a screening questionnaire for tobacco/nicotine dependence according to ICD-10, DSM-III-R, and DSM-IV. Addict Behav 24 (1999) 155-166
19. Heatherton T., Kozlowski L., Frecker R., and Fagerstrom K. The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86 (1991) 1119-1127
20. Oncken C., Gonzales D., Nides M., et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 166 (2006) 1571-1577
21. Fiore M. Treating tobacco use and dependence: An introduction to the US Public Health Service Clinical Practice Guideline. Respir Care 45 (2000) 1196-1199
22. NIH publication 03-1647. National Cancer Institute. Clearing the Air: Quit Smoking Today (2003), National Institutes of Health, Washington, DC
23. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res 4 (2002) 149-159
24. West R., Hajek P., Stead L., and Stapleton J. Outcome criteria in smoking cessation trials: Proposal for a common standard. Addiction 100 (2005) 299-303
25. Hurt R., Sachs D., Glover E., et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337 (1997) 1195-1202
26. Gonzales D., Bjornson W., Durcan M., et al. Effects of gender on relapse prevention in smokers treated with bupropion SR. Am J Prev Med 22 (2002) 234-239
27. Hughes J., Keely J., Niaura R., et al. Measures of abstinence in clinical trials: Issues and recommendations [published correction appears in Nicotine Tob Res. 2003;5:603]. Nicotine Tob Res 5 (2003) 13-25
28. Hughes J., and Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43 (1986) 289-294
29. Cappelleri J., Bushmakin A., Baker C., et al. Revealing the multidimensional framework of the Minnesota Nicotine Withdrawal Scale. Curr Med Res Opin 21 (2005) 749-760
30. Ohishi T., Green J., Nakamura M., and Ohashi J. Development of Japanese version of smoking cessation questionnaires. Jpn Pharmacol Ther 33 (2005) 141-156
31. Cox L., Tiffany S., and Christen A. Evaluation of the Brief Questionnaire of Smoking Urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res 3 (2001) 7-16
32. May 7 [E-pub ahead of print]. Cappelleri J., Bushmakin A., Baker C., et al. Multivariate framework of the Brief Questionnaire of Smoking Urges. Drug Alcohol Depend (2007)
33. Rose J., Behm F., and Westman E. Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy. Exp Clin Psychopharmacol 6 (1998) 331-343
34. Cappelleri J., Bushmakin A., Baker C., et al. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav 32 (2007) 912-923
35. Ruberg S. Dose response studies. II. Analysis and interpretation [published correction appears in J Biopharm Stat. 1996;6:375]. J Biopharm Stat 5 (1995) 15-42
36. Fagerstrom K., Kunze M., Schoberberger R., et al. Nicotine dependence versus smoking prevalence: Comparisons among countries and categories of smokers. Tob Control 5 (1996) 52-56